Rare disease news, mapped to the diseases behind the headlines. AI-classified across pipeline, policy, funding, science, and community.
Be among the first to receive Kisho Intelligence Briefings
Showing news related to
Showing 1–1 of 1 stories
New immunotherapy combinations for relapsed or refractory follicular lymphoma show promising efficacy in recent phase III trials. The addition of tafasitamab or epcoritamab to lenalidomide–rituximab (R2) offers potential new treatment options for patients.
Read full storyGet the week's most important rare disease developments — pipeline moves, policy changes, and funding signals — delivered to your inbox every Monday.
Free weekly briefing. Unsubscribe anytime.